Neurocognitive and clinical predictors of long-term outcome in adolescents at ultra-high risk for psychosis: a 6-year follow-up

PLoS One. 2014 Apr 4;9(4):e93994. doi: 10.1371/journal.pone.0093994. eCollection 2014.

Abstract

Background: Most studies aiming to predict transition to psychosis for individuals at ultra-high risk (UHR) have focused on either neurocognitive or clinical variables and have made little effort to combine the two. Furthermore, most have focused on a dichotomous measure of transition to psychosis rather than a continuous measure of functional outcome. We aimed to investigate the relative value of neurocognitive and clinical variables for predicting both transition to psychosis and functional outcome.

Methods: Forty-three UHR individuals and 47 controls completed an extensive clinical and neurocognitive assessment at baseline and participated in long-term follow-up approximately six years later. UHR adolescents who had converted to psychosis (UHR-P; n = 10) were compared to individuals who had not (UHR-NP; n = 33) and controls on clinical and neurocognitive variables. Regression analyses were performed to determine which baseline measures best predicted transition to psychosis and long-term functional outcome for UHR individuals.

Results: Low IQ was the single neurocognitive parameter that discriminated UHR-P individuals from UHR-NP individuals and controls. The severity of attenuated positive symptoms was the only significant predictor of a transition to psychosis and disorganized symptoms were highly predictive of functional outcome.

Conclusions: Clinical measures are currently the most important vulnerability markers for long-term outcome in adolescents at imminent risk of psychosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Case-Control Studies
  • Cognition*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Models, Psychological
  • Neuropsychological Tests
  • Patient Outcome Assessment
  • Prognosis
  • Psychiatric Status Rating Scales
  • Psychotic Disorders / diagnosis*
  • Psychotic Disorders / psychology*
  • ROC Curve
  • Risk

Grants and funding

This study was supported by a grant from ZON-MW, the Netherlands organization for health research and development (project # 2630.0001). Tim Ziermans was supported by a COFAS Marie Curie fellowship grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.